ZA200800905B - Use of 3,11B-CIS-Dihydrotetrabenazine for the treatment of symptoms of huntington's disease - Google Patents

Use of 3,11B-CIS-Dihydrotetrabenazine for the treatment of symptoms of huntington's disease

Info

Publication number
ZA200800905B
ZA200800905B ZA200800905A ZA200800905A ZA200800905B ZA 200800905 B ZA200800905 B ZA 200800905B ZA 200800905 A ZA200800905 A ZA 200800905A ZA 200800905 A ZA200800905 A ZA 200800905A ZA 200800905 B ZA200800905 B ZA 200800905B
Authority
ZA
South Africa
Prior art keywords
dihydrotetrabenazine
huntington
cis
symptoms
disease
Prior art date
Application number
ZA200800905A
Other languages
English (en)
Inventor
Robert Tridgett
Thierry Filloux
Original Assignee
Ie Cambridge Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ie Cambridge Lab Ltd filed Critical Ie Cambridge Lab Ltd
Publication of ZA200800905B publication Critical patent/ZA200800905B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200800905A 2005-07-14 2006-07-13 Use of 3,11B-CIS-Dihydrotetrabenazine for the treatment of symptoms of huntington's disease ZA200800905B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0514501.6A GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ZA200800905B true ZA200800905B (en) 2010-04-28

Family

ID=34897233

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800905A ZA200800905B (en) 2005-07-14 2006-07-13 Use of 3,11B-CIS-Dihydrotetrabenazine for the treatment of symptoms of huntington's disease

Country Status (24)

Country Link
US (1) US20080319000A1 (xx)
EP (2) EP2027861B1 (xx)
JP (1) JP2009501202A (xx)
KR (1) KR20080030666A (xx)
CN (1) CN101282726A (xx)
AT (2) ATE522215T1 (xx)
AU (1) AU2006268098B2 (xx)
CA (1) CA2615077A1 (xx)
CY (1) CY1108653T1 (xx)
DE (1) DE602006002982D1 (xx)
DK (1) DK1885363T3 (xx)
ES (1) ES2314931T3 (xx)
GB (1) GB0514501D0 (xx)
HK (1) HK1111085A1 (xx)
HR (1) HRP20080677T3 (xx)
ME (1) ME01629B (xx)
NZ (1) NZ565522A (xx)
PL (1) PL1885363T3 (xx)
PT (1) PT1885363E (xx)
RS (1) RS50626B (xx)
RU (1) RU2409365C2 (xx)
SI (1) SI1885363T1 (xx)
WO (1) WO2007007105A1 (xx)
ZA (1) ZA200800905B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
BRPI0718247B1 (pt) 2006-11-08 2021-09-21 Neurocrine Biosciences, Inc. Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
CN104744456A (zh) * 2010-06-01 2015-07-01 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3057548A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201808464D0 (en) * 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
WO2021011500A2 (en) * 2019-07-16 2021-01-21 Rush University Medical Center Use of a benzoate containing composition to treat neurodegenerative disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3159638A (en) * 1964-12-01 Xcha-chj
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3009918A (en) * 1961-11-21 Chz ch
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US2843591A (en) * 1958-07-15 Method for preparing same
US3123609A (en) * 1964-03-03 Benzo
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US3132147A (en) * 1964-05-05
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
JPS4836303B1 (xx) * 1968-12-27 1973-11-02
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
NO166268C (no) * 1985-07-30 1991-07-03 Glaxo Group Ltd Innretning for administrering av medikamenter til pasienter.
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
JP2004501083A (ja) * 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia

Also Published As

Publication number Publication date
CA2615077A1 (en) 2007-01-18
CY1108653T1 (el) 2014-04-09
EP2027861B1 (en) 2011-08-31
ATE409481T1 (de) 2008-10-15
DK1885363T3 (da) 2008-12-08
AU2006268098A1 (en) 2007-01-18
PT1885363E (pt) 2009-01-08
US20080319000A1 (en) 2008-12-25
RS50626B (sr) 2010-06-30
ME01629B (me) 2010-06-30
HRP20080677T3 (en) 2009-02-28
ES2314931T3 (es) 2009-03-16
GB0514501D0 (en) 2005-08-24
HK1111085A1 (en) 2008-08-01
WO2007007105A1 (en) 2007-01-18
AU2006268098B2 (en) 2011-02-17
SI1885363T1 (sl) 2009-02-28
JP2009501202A (ja) 2009-01-15
CN101282726A (zh) 2008-10-08
NZ565522A (en) 2010-04-30
EP1885363B1 (en) 2008-10-01
RU2409365C2 (ru) 2011-01-20
RU2008105590A (ru) 2009-08-20
DE602006002982D1 (de) 2008-11-13
KR20080030666A (ko) 2008-04-04
PL1885363T3 (pl) 2009-05-29
ATE522215T1 (de) 2011-09-15
EP2027861A1 (en) 2009-02-25
EP1885363A1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
HK1111085A1 (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease
HK1105893A1 (en) Compounds, compositions and methods of inhibiting a-synuclein toxicity
HK1121674A1 (en) Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer angiopoietin-2
WO2006091693A3 (en) Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
IL176393A (en) Patterned laser treatment of the retina
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2004004609A3 (fr) Immobilisateur dynamique elastique pour doigts ou orteils
GB0521716D0 (en) Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
DK1732648T3 (da) Sygdomsbehandling
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
UA99093C2 (ru) Применение фенофибрата или его производного для лечения диабетической ретинопатии
RU2002103738A (ru) Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний